Clinical InvestigationsRisk and predictors of mortality after implantable cardioverter-defibrillator implantation in patients with sarcoid cardiomyopathy
Section snippets
Background
Cardiac sarcoidosis (CS) is a type of non-ischemic cardiomyopathy (NICM) characterized by patchy granulomatous infiltration of the myocardium. Approximately 5% of sarcoidosis patients demonstrate overt cardiac involvement and up to 25% have clinically silent cardiac involvement based on pathological or imaging findings.1,2 The overall prognosis of patients with CS has previously been shown to be favorable with a 97% transplant-free survival at 1-year which decreases to 90% at 5 years and 83% at
Data sources
The NCDR ICD Registry was established in 2005 by the American College of Cardiology and the Heart Rhythm Society as a centralized data registry for patients undergoing ICD implantations. The registry met the Centers for Medicare and Medicaid Services (CMS) data collection requirements and in early 2006 CMS mandated that all Medicare patients receiving primary prevention ICDs be included in the registry; however, 90% of participating hospitals reported on other patient populations such as those
Baseline patient population and propensity matched cohort
There were 917,615 patients in the ICD Registry between April 1, 2010 and December 31, 2015. After excluding patients with a prior ICD (n = 398,055) or pacemaker (n = 54,776), patients with an epicardial system (n = 11,596), and patients with cardiac amyloidosis (n = 593), 452,595 patients comprised the study sample (Figure 1). Of these patients, 2,162 had CS and 450,433 had NICM. The baseline characteristics of the entire cohort prior to propensity matching are shown in Supplemental Table I.
Discussion
In this study of 1,638 patients with CS implanted with ICDs, mortality rates at 2 years were similar to propensity matched NICM patients. Among patients with CS, risk factors for 2-year mortality included presence of heart failure and severity of heart failure (NYHA class III or IV), atrial arrhythmias, chronic lung disease, renal dysfunction (creatinine >2 mg/dL), and paced rhythm. This information may help inform clinicians and patients regarding mortality risk in those with CS considering
Author contributions
Angela Y. Higgins: Conceptualization, methodology, writing-original draft, review and editing, visualization. Amarnath R. Annapureddy: Conceptualization, methodology, writing- review and editing. Yongfei Wang: Methodology, formal analysis, data curation, writing- review and editing. Karl E. Minges: Methodology, writing- review and editing, project administration. Lavanya Bellumkonda: Writing- review and editing. Rachel Lampert: Writing- review and editing. Lynda E. Rosenfeld: Writing- review
Funding
This research was supported by the American College of Cardiology (ACC) Foundation's National Cardiovascular Data Registry (NCDR). The views expressed represent those of the author(s) and do not necessarily represent the official views of the NCDR or its associated professional societies (www.ncdr.com).
Data statement
Data are available upon reasonable request.
Declaration of interest
Dr Minges and Yongfei Wang receive salary support for analytic services provided to the American College of Cardiology. Dr Lampert reports research grants from Medtronic and Abbott Laboratories/St. Jude Medical and serves on Medtronic advisory board and receives moderate honoraria. Dr Rosenfeld reports fellowship support and stock ownership for Abbott Laboratories and fellowship support from Boston Scientific and Medtronic. Dr Jacoby reports being on the speaker's bureau and an advisory board
References (38)
- et al.
Outcomes in patients with high-degree atrioventricular block as the initial manifestation of cardiac sarcoidosis
Am J Cardiol
(2015) - et al.
Trends in U.S. cardiovascular care: 2016 Report from 4 ACC National Cardiovascular Data Registries
J Am Coll Cardiol
(2017) - et al.
The National Cardiovascular Data Registry (NCDR) data quality brief: the NCDR data quality program in 2012
J Am Coll Cardiol
(2012) - et al.
The National ICD Registry: now and into the future
Heart Rhythm
(2006) - et al.
Linking inpatient clinical registry data to Medicare claims data using indirect identifiers
Am Heart J
(2009) - et al.
A primer and comparative review of major US mortality databases
Ann Epidemiol
(2002) - et al.
ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy: a report of the American College of Cardiology Foundation appropriate use criteria task force, Heart Rhythm Society, American Heart Association, American Society of Echocardiography, Heart Failure Society of America, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance
Heart Rhythm
(2013) - et al.
Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia–AMIOVIRT
J Am Coll Cardiol
(2003) - et al.
Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone
Am J Cardiol
(2001) - et al.
Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11)
Am J Med
(1977)